![]()
3-[(2-chlorophenyl)methyl] -7-thia-3-azabicyclo[4.3.0] nona-8,10-diene
Absorption
Ticlopidine is rapidly absorbed with peak levels (T max ) occurring about 2 after dose. The drug is greater than 80% absorbed. Administration after meals results in a 20% increase in the AUC. Ticlopidine is 98% bound to plasma proteins.
Metabolism
Ticlopidine is metabolized extensively by the liver; only trace amounts are detected in urine.
Elimination
Ticlopidine t ½ is 4 to 5 days.
Special Populations
Hepatic Function Impairment
Average plasma concentration is slightly higher in cirrhosis.
Antacids
May reduce ticlopidine absorption.
Aspirin
Increased effect of aspirin on collagen-induced platelet aggregation.
Cimetidine
Elevated ticlopidine levels with possible increase in therapeutic and toxic effects.
Theophylline
Elevated serum theophylline concentrations, increasing risk of toxicity.
Phenytoin
Elevated phenytoin plasma levels with associated somnolence and lethargy have been reported. Exercise caution when administering with ticlopidine.
本品若同時併用丹參、當歸、川紅花、藏紅花併用,可能會增強抗凝血作用。
本品若同時併用吉林參、吉林參鬚、高麗參、西洋參併用,可能會降低抗凝血作用。
1.限無法忍受acetylsalicylic acid (Aspirin) 或對acetylsalicylic acid (Aspirin) 有禁忌而需使用抗血小板製劑之病患使用(88/9/1)。
2.原則上本類製劑與acetylsalicylic acid (Aspirin) 不宜合併使用,僅於冠狀動脈支架植入術後三個月內,得依病情需要合併使用。(87/4/1、90/1/1)
3.申報費用時需註明放置支架 (stent) 之日期。(87/4/1、90/1/1、100/7/1)



